US Suspends Federal Funding To Wuhan Lab Over Non-Compliance

The U.S. has suspended federal funding to China’s Wuhan Institute of Virology (WIV) for failing to provide documentation related to concerns over biosafety protocol violations at the facility that has faced questions for years over the origins of the COVID-19 pandemic.

The U.S. Department of Health and Human Services (HHS) also said it wants to bar the Chinese research body from participating in government procurement and non-procurement programs going forward.

WIV has not received federal funding from the National Institutes of Health (NIH), the U.S. medical research agency, since July 2020, according to an HHS statement on Wednesday.

The action was taken on Monday following a months-long review that led the HHS to find that “WIV is not compliant with federal regulations and is not presently responsible”, according to a memo from the department.

“The move was undertaken due to WIV’s failure to provide documentation on WIV’s research requested by NIH related to concerns that WIV violated NIH’s biosafety protocols,” an HHS spokesperson said in a statement.

The institute could not immediately be reached outside of regular business hours.

The origins of the coronavirus pandemic have been a matter of furious debate around the world almost since the first human cases were reported in Wuhan in late 2019.

U.S. Republicans released a report in 2021 citing “ample evidence” that WIV scientists were working to modify coronaviruses to infect humans and such manipulation could be hidden.

In June 2023, U.S. intelligence agencies found no direct evidence that the COVID-19 pandemic stemmed from an incident at the WIV.

FBI Director Christopher Wray said in February his agency had assessed for some time that the origins of the pandemic were “most likely a potential lab incident” in the Chinese city of Wuhan. China said this claim had “no credibility whatsoever”.

 

Source Link

Recommended Articles

New NFIB Survey: Small Businesses Report Reduced Optimism

The NFIB Small Business Optimism Index fell 0.6 points in May to 95.3, remaining below its 52-year average of 98.0. The Uncertainty Index rose 3 points from April to 91, remaining well above its historical average of 68. As reported in NFIB’s monthly Jobs Report, the NFIB Small Business Employment Index remained essentially flat, registering 100.3 in May. ...

Read More

Trump Announces TrumpRx Expansion, Adding 160 More Drugs

President Trump on Friday announced that over 100 prescription medications would be added to his administration’s direct-to-consumer drug platform, TrumpRx, the second expansion of the initiative in as many months. “I am pleased to announce that TrumpRx.gov is adding another 160 Prescription Drugs, at highly discounted prices, for a new total of over 800 of the most commonly-used Prescription Drugs,” ...

Read More

Skyrocketing GLP-1 Demand Creates Major Financial Strain For Employers

GLP-1 drugs are a double-edged sword for the nation’s employers. Although they are having a demonstrable effect on workplace health, the high cost is putting a strain on their budgets. GLP-1s, known by brand names such as Ozempic, Wegovy, Mounjaro or Zepbound, originally were developed to help regulate blood sugar in people with Type 2 ...

Read More

Judge Throws Out Policy Imposing $100,000 Fees for Skilled Worker Visas

A Trump administration initiative to impose $100,000 fees on employers seeking visas for skilled foreign workers amounts to an unlawful tax on those companies and must be voided “in its entirety,” a federal judge ruled on Monday. The decision by Judge Leo T. Sorokin of the Federal District Court for the District of Massachusetts nullified ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square